摘要
目的观察巴曲酶治疗早期脑梗死的近期疗效及安全性。方法80例脑梗死病例采用巴曲酶10、5、5BU隔日静滴3次,用常规治疗组170例作对照,治疗前后进行临床神床功能和日常生活能力(BI)评分,同时测定凝血酶原时间(PT)、凝血活酶时间(APTT)、血黏度及纤维蛋白原浓度。结果巴曲酶可明显改善临床神经功能及日常生活能力,可降低血浆纤维蛋白原含量,降低血黏度,治疗前后有显著性差异(P<0.01);疗效明显好于对照组,差异有显著性(P<0.01)。结论巴曲酶治疗早期脑梗死疗效明显、安全性高。
Objective To study the near curative effect and safety of Batroxobin injection for nonage cerebral infarction. Methods Subjects were classified into Batroxobin injection group and control group. Batroxobin injection group （80 subjects） accepted Batroxobin injection 10BU, 5BU, 5BU by means of every other day intraverous drip on the base of conventional therapy. Control group only accepted conventional therapy. All subjects were assessed by clinical nervous function score and Barthel index（BI） before and after treatment. Simultaneous PT,APTT,blood viscosity and fibrinogen of them were determinated. Results After treatment , not only clinical nervous function and BI score were improved, but also blood viscosity and fibrinogen were declined by Batroxobin injection in Batroxobin injection group, and were significantly different from those before treatment（P〈0. 01）. Also, the curative effect of Batroxobin injection was better than that of control group（P〈0.01）. Conclusion Batroxobin injection is very effective and safe in the treatment of nonage eerebal infarction.
出处
《中国实用神经疾病杂志》
2008年第11期21-23,共3页
Chinese Journal of Practical Nervous Diseases
关键词
巴曲酶
脑梗死
近期疗效
安全性
Batroxobin
Cerebral infarction
Near curative effect
Safety
